Anti-fibrogenic strategies and the regression of fibrosis
- 30 April 2011
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Gastroenterology
- Vol. 25 (2), 305-317
- https://doi.org/10.1016/j.bpg.2011.02.011
Abstract
No abstract availableThis publication has 121 references indexed in Scilit:
- Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cellsHepatology, 2010
- TGF‐β inactivation and TGF‐α overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancerInternational Journal of Cancer, 2010
- Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver DiseaseGastroenterology, 2009
- Epithelial-to-mesenchymal transitions in the liverHepatology, 2009
- TGF-β Receptor Inactivation and Mutant Kras Induce Intestinal Neoplasms in Mice via a β-Catenin-Independent PathwayGastroenterology, 2009
- CCR2 promotes hepatic fibrosis in miceHepatology, 2009
- Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver developmentHepatology, 2008
- Senescence of Activated Stellate Cells Limits Liver FibrosisCell, 2008
- Stem Cell Therapy for Liver Disease: Parameters Governing the Success of Using Bone Marrow Mesenchymal Stem CellsGastroenterology, 2008
- NOX in liver fibrosisArchives of Biochemistry and Biophysics, 2007